<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05120830</url>
  </required_header>
  <id_info>
    <org_study_id>ITL-2002-CL-001</org_study_id>
    <nct_id>NCT05120830</nct_id>
  </id_info>
  <brief_title>NTLA-2002 in Adults With Hereditary Angioedema (HAE)</brief_title>
  <acronym>NTLA-2002</acronym>
  <official_title>Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intellia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intellia Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the safety, tolerability, activity,&#xD;
      pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema&#xD;
      (HAE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of NTLA-2002 as determined by adverse events (AEs)</measure>
    <time_frame>From NTLA-2002 infusion up to week 104 post-infusion</time_frame>
    <description>(Phase 1 only)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated efficacy as determined by measurement of change from baseline in HAE attack rate</measure>
    <time_frame>From study drug infusion up to week 104 post-infusion, primary observation period change in attack rate 16 weeks post-infusion</time_frame>
    <description>(Phase 2 only)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of NTLA-2002 as determined by HAE attack rate (Weeks 1-16, Weeks 5-16</measure>
    <time_frame>From NTLA-2002 infusion up to week 104 post-infusion</time_frame>
    <description>(Phase 1 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total plasma kallikrein protein level</measure>
    <time_frame>From NTLA-2002 infusion up to week 104 post-infusion</time_frame>
    <description>(Phase 1 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine concentrations for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA</measure>
    <time_frame>From NTLA-2002 infusion up to week 104 post-infusion</time_frame>
    <description>(Phase 1 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of NTLA-2002 as determined by AEs</measure>
    <time_frame>From study drug infusion up to week 104 post-infusion</time_frame>
    <description>(Phase 2 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HAE attack rate (Weeks 5-16)</measure>
    <time_frame>From study drug infusion up to week 104 post-infusion</time_frame>
    <description>(Phase 2 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in number of HAE attacks requiring acute therapy (Weeks 1-16, Weeks 5-16)</measure>
    <time_frame>From study drug infusion up to week 16 post-infusion</time_frame>
    <description>(Phase 2 only)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>Phase 1 Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants, assigned to one of 3 dose-escalation cohorts, will receive a single dose of NTLA-2002 on Day 1 and will then be followed for up to 24 months ; primary observation period is 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Experimental Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants, randomized to NTLA-2002 will be assigned to one of 2 dose levels, will receive a single dose of NTLA-2002 on Day 1 and will then be followed for up to 24 months; primary observation period is 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Placebo Comparator Study Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to placebo will be assigned to a matching IV normal saline administration on day 1 and will then be followed for up to 24 months Primary observation period = 16 weeks (~4 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological NTLA-2002</intervention_name>
    <description>CRISPR/Cas9 gene editing system delivered by LNP for IV administration</description>
    <arm_group_label>Phase 1 Study Arm</arm_group_label>
    <arm_group_label>Phase 2 Experimental Study Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline IV Administration</intervention_name>
    <description>The administration of IV normal saline</description>
    <arm_group_label>Phase 2 Placebo Comparator Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years&#xD;
&#xD;
          2. Diagnosis of HAE Types I or II&#xD;
&#xD;
          3. Ability to provide evidence of HAE attacks to meet the screening requirement&#xD;
&#xD;
          4. Subjects must have access to, and the ability to use, â‰¥ 1 acute medication(s) to treat&#xD;
             angioedema attacks.&#xD;
&#xD;
          5. Adequate chemistry and hematology measures at screening&#xD;
&#xD;
          6. Subjects must agree not to participate in another interventional study for the&#xD;
             duration of this trial.&#xD;
&#xD;
          7. Subjects must be capable of providing signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent diagnosis of any other type of recurrent angioedema&#xD;
&#xD;
          2. Subjects who have known negative reaction or hypersensitivity to any lipid&#xD;
             nanoparticles (LNP) component.&#xD;
&#xD;
          3. Any condition that, in the Investigator's opinion, could adversely affect the safety&#xD;
             of the subject.&#xD;
&#xD;
          4. Unwilling to comply with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Manager at Intellia</last_name>
    <phone>833-888-0387</phone>
    <email>clinicalscience@intelliatx.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

